inflammatory disease targets
Featured Story

New Targets for the Treatment of Inflammatory Diseases?

Research by the University of Bristol, performed in collaboration with KWS BioTest, a Charles River company, has provided insight on the way our white blood cells and clotting cells control their interactions with each other.

The study focused on RalA and RalB GTPases, two molecular switches that are important regulators of cell growth, cancer metastasis, and granule secretion. The researchers studied the role of RalA and RalB in controlling how platelets interact with immune cells to cause inflammation.

The findings, published in Arteriosclerosis, Thrombosis, and Vascular Biology, could lead to the development of new treatments for a range of inflammatory diseases, including rheumatoid arthritis, asthma, and inflammatory bowel disease.

For more information, read the University of Bristol press release.